This is an extended proposal from the 2022 economic development agreement between Brazos County and Fujifilm Biotechnologies.

RNA gene scissors (CRISPR-Cas13) are gaining significant attention as a next-generation gene therapy with fewer side effects.

This is a developing news story. Please check back soon for updates. The FDA granted VG801 rare pediatric disease designation ...

The US Food and Drug Administration has granted Nuevocor permission to begin a first-in-human trial of NVC-001, a gene therapy it is developing for LMNA-related dilated cardiomyopathy (LMNA-DCM), the ...

Two Italian women in their twenties on Tuesday received pioneering gene therapy for rare hereditary blood diseases in Pavia ...

An autoantibody associated with systemic lupus erythematosus may help improve the performance of immune checkpoint inhibitor ...

Glioblastoma has been deadly and hard to treat, but researchers say they’ve made progress with bivalent CAR T-cell therapy ...

Siegfried Priglinger, MD discussed research he presented focused on pediatric patients with inherited retinal diseases with ...

GenEditBio has dosed the first subject in an investigator-initiated trial of its in vivo genome editing programme, GEB-101, ...

A team of researchers at the University of Minnesota recently completed a human trial for a novel gene-editing treatment, ...